Progesterone in Gender Affirming Hormone Therapy Study
Emory University · NCT06807580
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–60 · Men only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 2
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- May 12, 2025
- Record last updated
- December 24, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study aims to study the effects of Oral Progesterone in Transgender Women. The primary goal is to study the effect of progesterone on psychological distress and secondarily on sleep quality, breast size, quality of life and gender congruence and cardiovascular risk.
Being studied: Placebo; Progesterone
Conditions: Transgender Women
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Participants will be transgender women, who have been on gender-affirming hormone therapy for at least 6 months before the start of the study.
Exclusion Criteria
- Peanut allergy
- Liver disease (liver enzyme elevations and/or evidence of acute or chronic hepatitis). In our lab, the upper limit of normal for aspartate aminotransferase (AST) is 39, and the upper limit of normal for alanine aminotransferase (ALT) is 52.
- Stage 4/5 chronic kidney disease
- Congestive heart failure
- Medical disease or medication use associated with gynecomastia (i.e tumor, hyperthyroidism, chronic kidney disease, cirrhosis, ACE inhibitors, statins, haloperidol, tricyclic antidepressants, atypical antipsychotics)
- Pre-existing cardiovascular disease
- Prior or current history of thromboembolism, known clotting disorders, current or recent anti-thrombotic therapy for venous thromboembolism.
- History of breast cancer
- Prior progesterone use
- Uncontrolled depression and/or suicidal ideation
- Current hypothyroidism (even if controlled with treatment) Progesterone in Gender Affirming Hormone Therapy 9 Version #4, 10/30/24
- Cannabis use of greater than 1 use/week in the past 3 months
- Previously identified BRCA 1 or 2 gene mutation or other familial breast cancer.
- Abnormal mammogram (if indicated - for patients above the age of 50 and on estrogen for 5 or more years OR positive family history of breast cancer) with results of BIRADS 3 or higher. Subjects with a BIRADS 0 mammogram must have undergone additional imaging demonstrating BIRADS 1 or 2 prior to enrollment.
- Have had or are planning to undergo breast enhancement or gender affirming top surgery in the next 6 months
- Uncontrolled hypertension, defined as systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mmHg.
- Triglycerides ≥ 500 mg/dL.
- In our lab, the upper limit of normal for aspartate aminotransferase (AST) is 39, and the upper limit of normal for alanine aminotransferase (ALT) is 52.
- Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m2.
- Estradiol levels outside the stable range (100-300 pg/mL)
- Heavy smoking, defined as 25+ cigarettes per day
- Non-English speaking or those with limited English proficiency
Recruiting US locations
Emory Transgender Clinic
Atlanta, GA 30308
Site contact: Vin Tangpricha, MD, PhD · 404) 727-7254 · vin.tangpricha@emory.edu
Study contacts (from the official record)
- Vin Tangpricha, MD, PhD · 404-727-7254 · vin.tangpricha@emory.edu
- Kayla Tanya Patel, MD
Similar studies in Georgia
All healthy volunteers studies in Georgia →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Influenza Human Challenge Model
Emory University
- Location
- Atlanta, GA + 1 other US site
- Eligibility basics
- Ages 18–49
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A/Texas Flu Challenge
Emory University
- Location
- Atlanta, GA + 1 other US site
- Eligibility basics
- Ages 18–49
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study of BLB-201 RSV Vaccine in Infants and Children
Blue Lake Biotechnology Inc.
- Location
- Atlanta, GA + 13 other US sites
- Eligibility basics
- Ages 6 mo–5
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Decatur, GA + 49 other US sites
- Eligibility basics
- Ages 60+